Literature DB >> 18536759

Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.

T Christ1, E Wettwer, N Voigt, O Hála, S Radicke, K Matschke, A Várro, D Dobrev, U Ravens.   

Abstract

BACKGROUND AND
PURPOSE: This study was designed to establish the pathology-specific inhibitory effects of the IKur/Ito/IK,ACh blocker AVE0118 on atrium-selective channels and its corresponding effects on action potential shape and effective refractory period in patients with chronic AF (cAF). EXPERIMENTAL APPROACH: Outward K+-currents of right atrial myocytes and action potentials of atrial trabeculae were measured with whole-cell voltage clamp and microelectrode techniques, respectively. Outward currents were dissected by curve fitting. KEY
RESULTS: Four components of outward K+-currents and AF-specific alterations in their properties were identified. Ito was smaller in cAF than in SR, and AVE0118 (10 microM) apparently accelerated its inactivation in both groups without reducing its amplitude. Amplitudes of rapidly and slowly inactivating components of IKur were lower in cAF than in SR. The former was abolished by AVE0118 in both groups, the latter was partially blocked in SR, but not in cAF, even though its inactivation was apparently accelerated in cAF. The large non-inactivating current component was similar in magnitude in both groups, but decreased by AVE0118 only in SR. AVE0118 strongly suppressed AF-related constitutively active IK,ACh and prolonged atrial action potential and effective refractory period exclusively in cAF. CONCLUSIONS AND IMPLICATIONS: In atrial myocytes of cAF patients, we detected reduced function of distinct IKur components that possessed decreased component-specific sensitivity to AVE0118 most likely as a consequence of AF-induced electrical remodelling. Inhibition of profibrillatory constitutively active IK,ACh may lead to pathology-specific efficacy of AVE0118 that is likely to contribute to its ability to convert AF into SR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536759      PMCID: PMC2518460          DOI: 10.1038/bjp.2008.209

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 2.  New ideas about atrial fibrillation 50 years on.

Authors:  Stanley Nattel
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Differences between outward currents of human atrial and subepicardial ventricular myocytes.

Authors:  G J Amos; E Wettwer; F Metzger; Q Li; H M Himmel; U Ravens
Journal:  J Physiol       Date:  1996-02-15       Impact factor: 5.182

4.  L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases.

Authors:  T Christ; P Boknik; S Wöhrl; E Wettwer; E M Graf; R F Bosch; M Knaut; W Schmitz; U Ravens; D Dobrev
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

5.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

Authors:  Z Wang; B Fermini; S Nattel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

Review 6.  Remodeling of cardiomyocyte ion channels in human atrial fibrillation.

Authors:  Dobromir Dobrev; Ursula Ravens
Journal:  Basic Res Cardiol       Date:  2003-05       Impact factor: 17.165

7.  Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.

Authors:  Erich Wettwer; Ottó Hála; Torsten Christ; Jürgen F Heubach; Dobromir Dobrev; Michael Knaut; András Varró; Ursula Ravens
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

8.  Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Authors:  Heinz Gögelein; J Brendel; K Steinmeyer; C Strübing; N Picard; D Rampe; K Kopp; A E Busch; M Bleich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-31       Impact factor: 3.000

9.  Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.

Authors:  Klaus J Wirth; Tobias Paehler; Bjoern Rosenstein; Karsten Knobloch; Thomas Maier; Jennifer Frenzel; Joachim Brendel; Andreas E Busch; Markus Bleich
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

10.  A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression.

Authors:  D J Snyders; M M Tamkun; P B Bennett
Journal:  J Gen Physiol       Date:  1993-04       Impact factor: 4.086

View more
  44 in total

Review 1.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

2.  K+ current changes account for the rate dependence of the action potential in the human atrial myocyte.

Authors:  Mary M Maleckar; Joseph L Greenstein; Wayne R Giles; Natalia A Trayanova
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-24       Impact factor: 4.733

Review 3.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

Review 4.  Ion Channels in the Heart.

Authors:  Daniel C Bartos; Eleonora Grandi; Crystal M Ripplinger
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

5.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

6.  Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes.

Authors:  A J Workman; G E Marshall; A C Rankin; G L Smith; J Dempster
Journal:  J Physiol       Date:  2012-06-25       Impact factor: 5.182

7.  Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts.

Authors:  Hassan Musa; Kuljeet Kaur; Ryan O'Connell; Matt Klos; Guadalupe Guerrero-Serna; Uma Mahesh R Avula; Todd J Herron; Jerômé Kalifa; Justus M B Anumonwo; José Jalife
Journal:  Heart Rhythm       Date:  2013-03-14       Impact factor: 6.343

8.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

9.  Increased thin filament activation enhances alternans in human chronic atrial fibrillation.

Authors:  Melanie A Zile; Natalia A Trayanova
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

10.  Mathematical simulations of ligand-gated and cell-type specific effects on the action potential of human atrium.

Authors:  Mary M Maleckar; Joseph L Greenstein; Natalia A Trayanova; Wayne R Giles
Journal:  Prog Biophys Mol Biol       Date:  2009-01-30       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.